Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

ABSTRACT:

Background

Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination.

Methods

Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles.

Results

Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipi

SUBMITTER: Boudewijns S 

PROVIDER: S-EPMC5007966 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature